For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Idec Pharmaceuticals Corporation

USPTO Granted Patents = 37

Trademarks = 2

Forward Citations = 2,907

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Roland A Newman (17 out of 30 patents)

Nabil Hanna (13 out of 40 patents)

Mitchell E Reff (9 out of 25 patents)

4. Peter Brams (8 out of 24 patents)

5. William H Rastetter (7 out of 18 patents)

6. Cheryl Janne Heard (6 out of 9 patents)

7. Amelia Nancy Black (5 out of 15 patents)

8. Ronald W Raab (5 out of 5 patents)

9. Edward E Walsh (5 out of 8 patents)

10. Li-Zhen Pan (5 out of 5 patents)

11. Soulaima Salim Chamat (5 out of 5 patents)

12. Darrell R Anderson (4 out of 22 patents)

13. Syamal Raychaudhuri (4 out of 8 patents)

14. Richard Spence Barnett (4 out of 13 patents)

15. Karen Retta McLachlan (4 out of 8 patents)

37 patents: Sort by Forward Citations

1. 6846476 - Treatment of B-cell associated diseases (2005-01-25),

2. 6841383 - Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same (2005-01-11),

3. 6682734 - Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma (2004-01-27),

4. 6506383 - Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies (2003-01-14),

5. 6455043 - Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody (2002-09-24),

6. 6451284 - Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy (2002-09-17),

7. 6440418 - Methods of treating autoimmune diseases with gp39-specific antibodies (2002-08-27),

8. 6413777 - Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same (2002-07-02),

9. 6413771 - Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof (2002-07-02),

10. 6300143 - Electrochemiluminescent assays for eukaryotic cells (2001-10-09),

11. 6270769 - Induction of cytotoxic T-lymphocyte responses (2001-08-07),

12. 6207858 - Regioselective synthesis of DTPA derivatives (2001-03-27),

13. 6197311 - Induction of cytotoxic T-lymphocyte responses (2001-03-06),

14. 6136310 - Recombinant anti-CD4 antibodies for human therapy (2000-10-24),

15. 6113898 - Human B7.1-specific primatized antibodies and transfectomas expressing (2000-09-05),

Idec Pharmaceuticals Corporation is a leading global biotechnology company that specializes in the development of innovative therapies to treat various forms of cancer. With a strong focus on research and development, Idec Pharmaceuticals has successfully introduced several groundbreaking drugs to the market, revolutionizing cancer treatment and improving patient outcomes. The company is committed to advancing the field of oncology and continues to invest in cutting-edge technologies and collaborations to further expand their portfolio of life-saving therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

37 Patents

#156 in San Diego, CA

#2,128 in California

#8,947 in US

#17,724 in the World

San Diego, CA, United States of America

Idec Pharmaceuticals Corporation

Forward Citations = 2,907

30 inventors:

Roland A Newman (17 out of 30 patents)

Nabil Hanna (13 out of 40 patents)

Mitchell E Reff (9 out of 25 patents)

4. Peter Brams (8 out of 24 patents)

5. William H Rastetter (7 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…